We’re excited to announce clinical study results supporting our lead investigational product ATX101, which we believe has potential to transform post-surgical pain management and recuperation for patients and their physicians. In a Phase 2B study in patients undergoing total knee replacement surgery, ATX101 achieved sustained post-surgical pain relief for up to four weeks and outperformed a standard of care active comparator on durability of effect, use of opioids to support pain relief and the potential for patients to return to day-to-day activities earlier. Allay is committed to pioneering ultra-sustained, non-opioid-based analgesic products that aid patient recovery while reducing the costs of these surgeries for patients, physicians and payors alike. These results provide clear guidance for the design of a pivotal clinical study as we move towards registration. We thank our investigators, staff and participating patients for helping us deliver this important clinical milestone. More in today’s press release: https://lnkd.in/ef9c9SYA #painmanagement #TKA #analgesic #bupivacaine #nonopioid #postsurgicalrecovery #drugdelivery #kneereplacement #orthopedics #orthopedicsurgery
Good to hear about continuing progress.
Awesome news! Congratulations to the Allay team!
Congratulations on the clinical study outcomes. This will be a game-changer for the treatment of post-op pain management.